Shanghai Yuansong Biotechnology Co., Ltd.
Shanghai Yuansong Biotechnology Co., Ltd.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | DNA Virus Infections, Infections, Neoplasms by Site, Thoracic Neoplasms, adenoviridae infectious disease, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, viral infectious disease | Recruiting | Early phase 1 | 2026-08-28 | NCT07793500 | |
| Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenoviridae infectious disease, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, viral infectious disease | Recruiting | Early phase 1 | 2026-04-20 | NCT07538128 |